Galactose Single Point (GSP), Residual Liver Function

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Galactose Single Point (GSP), Residual Liver Function trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (2 shown)

CompletedPhase 1/2

NCT04546022

GSP as an Novel Indicator for Residual Liver Function in Patients With Fatty Liver

The primary objective is to determine the galactose single point (GSP) cutoff values to discriminate subjects with different hepatic function. The secondary obj…

Location not specified210 participantsStarted 2007-07-05

Treatment: Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.

UnknownPhase 3

NCT03457311

Clinical Study for Development of Oral Galactose Single Point (OGSP) Solution (G.S.P. Oral Solution®)

The primary objective is to determine the oral galactose single point (OGSP) cutoff values to discriminate subjects with different hepatic function. The seconda…

Location not specified200 participantsStarted 2013-09-09

Treatment: G.S.P. Oral Solution 400 mg/ml